Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Division of Cardiology, Northwestern University, Chicago, IL, USA.
J Oncol Pharm Pract. 2021 Dec;27(8):2010-2013. doi: 10.1177/10781552211004698. Epub 2021 Mar 31.
We report the case of a woman who developed hyperlipidemia on lorlatinib therapy found to have minimal change disease. We review therapies for cancer known to alter the lipid profile, in addition to reviewing secondary hyperlipidemia workup. We also propose a mechanism for lorlatinib-induced hyperlipidemia.
A 63 year old woman with non-small cell lung adenocarcinoma on lorlatinib therapy develops marked hyperlipidemia. A secondary hyperlipidemia workup is performed which reveals nephrotic range proteinuria. Minimal change disease is found on renal biopsy. The hyperlipidemia was initially responsive to statin therapy, then required addition of ezetimibe.
This is a case of hyperlipidemia in a patient on lorlatinib. The case highlights that therapies for lung cancer and other malignancies have the potential to alter the lipid profile. We propose minimal change disease as a possible mechanism for lorlatinib-induced dyslipidemia. Additionally, we discuss the crucial aspects of secondary hyperlipidemia workup.
我们报告了一例在 lorlatinib 治疗中发生高脂血症的女性患者，其被发现患有微小病变性疾病。我们回顾了已知会改变血脂谱的癌症治疗方法，此外还回顾了继发性高脂血症的检查。我们还提出了 lorlatinib 诱导性高脂血症的机制。
一名 63 岁的女性患有非小细胞肺癌，正在接受 lorlatinib 治疗，出现明显的高脂血症。进行了继发性高脂血症检查，结果显示肾病范围的蛋白尿。肾活检发现微小病变性疾病。高脂血症最初对他汀类药物治疗有反应，然后需要加用依折麦布。
这是一例接受 lorlatinib 治疗的患者的高脂血症病例。该病例强调了肺癌和其他恶性肿瘤的治疗方法有可能改变血脂谱。我们提出微小病变性疾病可能是 lorlatinib 诱导的血脂异常的一种机制。此外，我们还讨论了继发性高脂血症检查的关键方面。
